arrow
K

Krina K. Patel

The University of Texas MD Anderson Cancer Center
H指数:28
被引数:4,612

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early treatment failure after ciltacabtagene autoleucel in multiple myeloma with high-risk features: implications for risk-informed care

具有高危特征的多发性骨髓瘤在应用cilta-cabtagene autoleucel治疗后早期失败:对风险知情护理的启示

2026-10-220
OAAI
Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study

在复发多发性骨髓瘤中,自体移植后使用达鲁单抗±泊马利度胺进行维持治疗:一项2期研究

2026-09-260
OAAI
Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
2026-08-310
OAAI
Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium
2026-07-270
OA
D-VRD induction and autologous transplant in patients ≥70 years

D-VRD诱导和自体移植在≥70岁患者中的应用

2026-06-050
OAAI
Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

遗传血统与复发/难治性多发性骨髓瘤患者接受伊decabtagene vicleucel治疗后结局和毒性的关联

2026-04-130
OAAI
Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma

西达基奥仑赛注射液(ciltacabtagene autoleucel)在重度预治疗复发或难治性多发性骨髓瘤患者中引发的细胞减少症和感染

2026-01-014
OA
Lenalidomide maintenance after delayed or salvage autologous stem cell transplantation

来那度胺维持治疗在延迟或挽救性自体造血干细胞移植后的应用

2026-01-010
PRE
Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma

延迟或挽救性自体造血干细胞移植治疗多发性骨髓瘤的结果

2025-12-050
PRE
Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy

Waldenström巨球蛋白血症患者停止Bruton酪氨酸激酶抑制剂(BTKi)治疗后的长期结局及治疗模式

2025-12-030
OAAI
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

外周髓外和骨旁浆细胞瘤对使用teclistamab治疗的多发性骨髓瘤患者治疗结局的影响:美国骨髓瘤免疫治疗联盟真实世界经验

2025-11-280
OAAI
The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis

系统性AL淀粉样变性中双特异性T细胞衔接疗法的安全性与有效性

2025-11-010
PRE
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response

多发性骨髓瘤患者对特克替玛初始无应答后延迟应答的预测因子

2025-10-110
OAAI
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium

氟达拉滨淋巴细胞清除暴露与伊达比特-维克鲁塞尔治疗后复发性/难治性多发性骨髓瘤的毒性相关:来自美国骨髓瘤免疫治疗联盟的真实世界经验

2025-09-170
PREAI